eligibility_summary
Adults ≥18, ECOG 0–1, histologically confirmed unresectable locally advanced/metastatic urothelial carcinoma, measurable disease (RECIST 1.1) and tumor tissue available. Phase Ib: failed/intolerant/refused standard therapy, Phase II: no prior systemic therapy. Exclude: active/uncontrolled CNS mets, prior TOPO1‑ADC, anti‑cancer tx ≤4 wks, RT ≤14 d or chest >30 Gy ≤6 mo, unresolved >G1 AEs, immunosuppression ≤14 d, ILD, prior ≥G3 irAEs (Ib), autoimmune disease, symptomatic ascites/effusions, uncontrolled cardiac disease.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06639347 tests a triple regimen in advanced urothelial carcinoma: 1) SHR-A2102: an antibody–drug conjugate (ADC) carrying a topoisomerase I inhibitor payload, binds a tumor cell-surface antigen (not specified), is internalized, and releases the payload to induce DNA damage and tumor cell death. 2) Adebrelimab: a monoclonal antibody PD-L1 inhibitor that blocks the PD-1/PD-L1 checkpoint to restore T‑cell antitumor activity. 3) SHR-8068: investigational anti-cancer agent, mechanism not specified in the registry. Targeted cells/pathways: tumor cells expressing the ADC’s antigen, DNA replication/Topoisomerase I pathway, the PD-1/PD-L1 immune checkpoint on tumor and immune cells (T cells/APCs). The aim is combined cytotoxicity plus immune activation.